As a rough estimate, the committee felt that about half of the deaths were preventable. In particular, they reported that of the patients for whom severity could be estimated, 61 (39%) appeared to have severe asthma, 14 (9%) were being treated for mild asthma and 76 (49%) for moderate asthma. It is likely that many patients who were treated as having mild or moderate asthma had poorly controlled undertreated asthma, rather than truly mild or moderate disease.
NZ reported 65 asthma deaths with a disproportional burden of Māori and Pacific Island people. It may well be that about half of these deaths were preventable. The selection of articles in this issue of Respiratory Research Review focuses on identifying trigger factors, including viral infections and fungal spores. Most articles reviewed improvements in our management strategies. The 'elephant in the room' certainly is adherence to asthma treatment; it seems very likely that we will only make real progress if we learn to work together as healthcare delivery teams.
We hope you enjoy the selection. Any ideas on how to further care for our patients are greatly appreciated. 
Kind regards

Respiratory Research Review
Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma Authors: Zhu J et al.
Summary:
These researchers performed immunohistochemical analyses of inflammatory cells infiltrating the bronchial mucosa before and after experimental rhinovirus infection in 10 individuals with asthma and 15 without. Rhinovirus infection was associated with significant increases from baseline in epithelial and subepithelial neutrophil counts in asthmatics only. Significant increases in subepithelial CD68+ macrophages were seen after rhinovirus infection in all subjects, but the increase was greater in asthmatics. Positive associations were seen between CD45+, CD68+ and CD20+ cell, neutrophil and eosinophil counts at postinfection day 4 and virus load (r=0. 50-0.72 [p=0.016-0.03] Comment: Rhinovirus infections are a strong trigger factor for acute exacerbations of asthma. These British researchers explored the mechanism after infecting participants with 10,000 units of rhinovirus via nasal spray and performing bronchial biopsies at baseline, 4 days and 6 weeks after infection. They described significant changes in the asthmatic group not seen in the controls and correlated them to spirometry and FENO measurements. The authors speculated that CD4 expression may have a protective effect. Bottom line: a viral dose-dependent increase in mucosal neutrophils, eosinophils and lymphocytes correlated with physiological measurements of asthma severity. Summary: These researchers surveyed 6346 parents of schoolchildren aged 6-15 years attending 44 schools across Taiwan, and measured fungal spores in classrooms, to assess allergic/asthmatic conditions. The respective prevalences of physician-diagnosed asthma, current asthma and asthma with symptoms reduced on holidays or weekends were 11.7%, 7.5% and 3.1%, and the respective geometric mean spore levels of total fungi, Aspergillus/ Penicillium and basidiospores were 2181, 49 and 318 spores/m 3 . Significant correlations were seen between both Aspergillus /Penicillium and basidiospore levels and both current asthma and asthma with symptoms reduced on holidays or weekends after adjusting for personal and school factors. Symptom relief during the weekend was reported for 41% of children with current asthma.
Reference
Comment: One of the outcomes of the British review of asthma deaths is a lack of effort in identifying trigger factors. Taiwanese researchers went to great effort to explore the role of fungal spores in classrooms. They borrowed the concept of 'asthma with symptoms reduced on holidays' (ASROH) from occupational asthma. The researchers collected fungal spores for 40 min in the centre of each classroom with air samplers placed at the height of children's respiratory zones in 44 schools. Their findings match the reports that reduced dampness in dwellings improves respiratory symptoms. Bottom line: a strong correlation between ASROH and high Aspergillus/Penicillium spore count has been observed.
Reference: Chest 2014;146(1):123-34 Abstract
Effects of weight loss on asthma control in obese patients with severe asthma Authors: Dias-Júnior SA et al.
Summary:
This study involved patients with severe uncontrolled asthma and moderate obesity, 22 of who were randomised to undergo treatment for obesity; a further 11 served as controls. The bodyweight reduction programme was associated with a significant improvement in asthma control, as determined by a reduction in mean ACQ score from 3.02 at baseline to 2.25 at 6 months, whereas ACQ scores were unchanged in controls (2.91 at baseline and 2.90 at 6 months). This improvement was not accompanied by changes in markers of airway inflammation or bronchial reactivity, but by an increase in FVC (forced vital capacity).
Comment:
The link between asthma and obesity is becoming clearer as both epidemics increase. Obesity probably affects asthma on several levels: a mechanical effect on the airways, an associated lack of fitness and the proinflammatory effect of 'adipokines' like leptin. Obesity-related asthma is associated with more severe disease, less response to steroids and worse clinical control. This group of Brazilian researchers reported on a cohort of patients who underwent a bodyweight reduction programme; about half of the patients managed to drop their weight significantly. Bottom line: weight loss leads to improved asthma symptoms without a change in FEV 1 or FENO. Summary: The effectiveness and safety of bronchial thermoplasty at 5 years' follow-up were reported for 162 participants from the Asthma Intervention Research 2 trial who had been treated with this therapy for severe, persistent asthma. Compared with rates during the 12 months before bronchial thermoplasty, the 5-year rates of severe exacerbations and ED visits were reduced by 44% and 78%, respectively, and had been consistently lower during each of the 5 years of follow-up. Respiratory-related adverse events and hospitalisations were similar for years 2-5 compared with the first year after bronchial thermoplasty. The average daily ICS dose decreased by 18% after bronchial thermoplasty, yet prebronchodilator FEV 1 values remained stable during this time. High-resolution CT scans revealed no structural abnormalities at year 5 that could have been attributed to bronchial thermoplasty.
Comment: About 5% of patients with asthma have severe, persistent symptoms despite optimal therapy. Bronchial thermoplasty delivered via a bronchoscope is thought to reduce smooth muscle hypertrophy. It has been shown to reduce exacerbations, ED visits, hospital admissions and time off school or work. Here the authors of the Asthma Intervention Research 2 trial reported their 5-year follow-up data, which included a scheduled repeat high-resolution CT scan. Despite a reduction in the steroid dose, the FEV 1 remained stable and exacerbations and ED visits continue to be reduced. Bottom line: bronchial thermoplasty can be added to the armamentarium for patients with severe, persistent asthma. The NZMA is your professional association, representing the collective interests of all doctors.
• Support and Representation • Publications . Symbicort 400/12 is not approved for use in the Symbicort SMART regime. Approved indication: For the regular treatment of asthma where use of combination inhaled corticosteroid and long acting beta-agonist is appropriate using either Symbicort Maintenance and Reliever Therapy (SMART) or Symbicort maintenance therapy. Contraindications & Precautions: Hypersensitivity to budesonide, eformoterol or inhaled lactose. Symbicort should not be initiated as emergency treatment for severe exacerbations or for patients with acutely worsening asthma symptoms. Care required for HPA axis suppression, when coadministering with inhibitors of CYP3A4 (e.g. ketoconazole, beta-blockers) or in patients with tuberculosis, severe cardiovascular disorders, diabetes, untreated hypokalaemia or thyrotoxicosis, pregnancy and lactation. Common side effects include headache, palpitations, tremor, oral candidiasis, mild throat irritation, coughing and hoarseness. Before prescribing please refer to the full product data sheet available at www.medsafe.govt.nz 4 March 2013. Symbicort is a fully funded Prescription Medicine. Special authority criteria and a prescription charge will apply, please refer to the Pharmaceutical Schedule. Symbicort Summary: Pregnant women of <20 weeks' gestation who had received antiasthma medications within the previous year were randomly allocated to a pharmacist-led intervention directed at improving maternal asthma control with multidisciplinary care, education and regular monitoring (n=29) or usual care (n=29). The intervention was associated with a significantly greater reduction in baseline ACQ score at 6 months compared with usual care (baseline-adjusted between-group difference -0.60 [p<0.001]), which was deemed to be clinically significant (>0.5). There were no reports of asthma-related oral corticosteroid use, hospital admission, ED visits or days off work.
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Comment: This multidisciplinary team is addressing asthma management during pregnancy, as good asthma control is beneficial for the mother and the foetus. Despite the well-established safety of ICSs, about a quarter of doctors would instruct their pregnant patients to decrease or discontinue asthma medication during pregnancy when asthma was well controlled. This Melbourne study by pharmacists randomised pregnant asthmatic patients to an intervention including education, monitoring and feedback and a control group. Their main outcome measure was asthma control measured by the asthma control test. Bottom line: a multidisciplinary approach of asthma management leads to a significant improvement of asthma symptoms. 
Reference
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Medication use in Indian children with asthma: the user's perspective Authors: Grover C et al.
Summary:
This research sought to explore views on asthma medication use with semistructured qualitative interviews in 20 children with asthma and a parent/carer recruited from two Indian hospitals. The main issues reported were poor parent and child understanding of the disease and medications, with apparent fears, misinformed beliefs and lack of self-management skills. Themes that emerged from the interviews with the children included self-image, resistance to medication use and lack of responsibility in medication taking.
Comment: This is another study led by pharmacists, this time from Sydney in co-operation with the University of Delhi in India. A strong focus of asthma care is on compliance and educational interventions; however, not many studies have explored the child's perspective. The authors used the qualitative tool of grounded theory methodology to explore the experiences of children and their caregivers regarding use of asthma medications. These results do not represent patients and doctors attitudes in our NZ culture; however, it highlights important aspects. Bottom line: steroid phobia, embarrassment using inhalers in public and a 'fatalistic attitude' were identified as barriers to asthma control.
Reference: Respirology 2013;18(5):807-13 Abstract
It's the adherence, stupid (that determines asthma control in preschool children)! Authors: Klok T et al.
Summary:
The relationship between ICS adherence and long-term asthma control was explored in 81 children aged 2-6 years with asthma using Smartinhaler ® devices. The median adherence rate was 87%, and asthma was well-controlled during follow-up in 79% of the children. An association was seen between an adherence rate of >80% and better asthma control, with no important confounders identified. Lower adherence rates were significantly associated with persistent mild symptoms (p=0.028).
Comment:
The results of the first study in this month's Respiratory Research Review were based on data from the Nexus6 Smartinhaler, which sends data on metered-dose inhaler usage to a central site. This advice was also used by a group of Dutch paediatricians to explore the relationship between adherence to asthma treatment and asthma control. Knowing that adherence will be reported led to a higher compliance rate with asthma therapy than in other studies. Still, as the title suggests, it was hardly surprising they came up with the bottom line: asthma care based on guidelines leads to well-controlled asthma -the key factor is adherence to ICS therapy.
